Epicrispr trial using Springbok AI twin shows positive clinical evidence of increased lean muscle, including results from an Australian site
FSHD Global welcomes today's announcement from Epicrispr Biotechnologies which shares positive clinical evidence from their ongoing trial which includes one Australian site in Sydney. Data was presented at the 33rd International Research Congress for FSHD today in Chicago.
This is the first clinical trial which utilises innovative AI digital twin developed by Springbok Analytics, proudly funded by our FSHD Global Research Foundation supporters, with funding contributions also received from Friends of FSH Research and FSHD Canada.
Read the full press release here: Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321
hashtag#clinicaltrials hashtag#fshd hashtag#medicalresearch
